Abstract
Objectives
To determine if the past presence of anti-double-strand (ds)DNA antibody (Ab) will predict subsequent disease activity in patients with systemic lupus erythematosus (SLE).
Methods
A longitudinal study of clinical and serological disease manifestations registered during 2,412 patient months of follow-up in a well-defined lupus cohort. Organ-specific disease manifestations, the modified SLE disease activity index (M-SLEDAI) score, disease flares (M-SLEDAI increase ≥3) and predictive value of anti-dsDNA Ab testing [by enzyme-linked immunoabsorbent assay (ELISA) and Crithidia luciliae immunofluorescence (CLIFT) assays] were related to past anti-dsDNA Ab status.
Results
Anti-dsDNA Ab was previously demonstrated in 54 (57%) patients (group 1), while they were not earlier detected in 40 (43%) patients (group 2). The number of patients experiencing flares (46 vs 25%, p<0.01), the total number of flares (75 vs 17, p<0,001) as well as overall (60 vs 24 per 100 patient years, p<0,001) and organ-specific flare rate were higher in group 1. After adjustment for control frequency, group 1 remained at a higher risk for renal flares [odds ratio (OR) 2.4; confidence interval (CI) 1.5–4.1], and group 2 was at a higher risk for skin flares (OR 0.7; CI 0.5–0.8). While anti-dsDNA Ab testing overall was performed slightly more often in group 1 (OR 1.45; CI 1.0–4.6), anti-dsDNA Ab testing during flares was similar in both groups.
Conclusion
The past presence of anti-dsDNA Ab identified patients with an increased risk of subsequent renal flares. However, as a new onset of anti-dsDNA Abs occurred late in the disease course, prior anti-dsDNA status was not adequate to predict disease flares.
Similar content being viewed by others
References
Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25(11):1271–1277
Hahn BH (1998) Antibodies to DNA. N Engl J Med 338(19):1359–1368
Pisetsky DS (1998) Anti-DNA antibodies in systemic lupus erythematosus: a case of mistaken identity? J Rheumatol 25(2):195–197
Rekvig OP, Andreassen K, Moens U (1998) Antibodies to DNA—towards an understanding of their origin and pathophysiological impact in systemic lupus erythematosus. Scand J Rheumatol 27(1):1–6
Isenberg DA, Ravirajan CT, Rahman A, Kalsi J (1997) The role of antibodies to DNA in systemic lupus erythematosus—a review and introduction to an international workshop on DNA antibodies held in London, May 1996. Lupus 6(3):290–304
Rekvig OP, Nossent JC (2003) Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms? Arthritis Rheum 48(2):300–312
Ho A, Magder LS, Barr SG, Petri M (2001) Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 44(10):2342–2349
Ho A, Barr SG, Magder LS, Petri M (2001) A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 44(10):2350–2357
Swaak AJ, Aarden LA, Statius van Eps LW, Feltkamp TE (1979) Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 22(3):226–235
Swaak AJ, Groenwold J, Bronsveld W (1986) Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis 45(5):359–366
ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG (1990) Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 33(5):634–643
Bootsma H, Spronk PE, ter Borg EJ, Hummel EJ, de Boer G, Limburg PC et al (1997) The predictive value of fluctuations in IgM and IgG class anti-dsDNA antibodies for relapses in systemic lupus erythematosus. A prospective long-term observation. Ann Rheum Dis 56(11):661–666
Williams RC Jr, Malone C, Blood B, Silvestris F (1999) Anti-DNA and anti-nucleosome antibody affinity—a mirror image of lupus nephritis? J Rheumatol 26(2):331–346
Zonana-Nacach A, Roseman JM, McGwin G Jr, Friedman AW, Baethge BA, Reveille JD et al (2000) Systemic lupus erythematosus in three ethnic groups. VI: Factors associated with fatigue within 5 years of criteria diagnosis. LUMINA Study Group. LUpus in MInority populations: NAture vs nurture. Lupus 9(2):101–109
Kavanaugh A (2001) The utility of immunologic laboratory tests in patients with rheumatic diseases. Arthritis Rheum 44(10):2221–2223
Kavanaugh AF, Solomon DH (2002) Guidelines for immunologic laboratory testing in the rheumatic diseases: anti-DNA antibody tests. Arthritis Rheum 47(5):546–555
Esdaile JM, Joseph L, Abrahamowicz M, Li Y, Danoff D, Clarke AE (1996) Routine immunologic tests in systemic lupus erythematosus: is there a need for more studies? J Rheumatol 23(11):1891–1896
Esdaile JM, Abrahamowicz M, Joseph L, MacKenzie T, Li Y, Danoff D (1996) Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 39(3):370–378
Rauch J, Hazeltine M, Tannenbaum H, Danoff D, Isenberg DA, Wild J et al (1990) Association of anti-DNA idiotype markers with clinical and serological manifestations in patients with systemic lupus erythematosus. J Rheumatol 17(2):178–185
Nossent HC (2001) Systemic lupus erythematosus in the Arctic region of Norway. J Rheumatol 28(3):539–546
Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 35(6):630–640
Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D et al (1994) Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: international validation. J Rheumatol 21(8):1468–1471
Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Bombardier C, Isenberg D et al (1992) Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 19(4):608–611
Haugbro K, Nossent JC, Winkler T, Figenschau Y, Rekvig OP (2004) Anti-dsDNA antibodies and disease classification in antinuclear antibody positive patients: the role of analytical diversity. Ann Rheum Dis 63(4):386–394
Olaussen E, Rekvig OP (1999) Screening tests for antinuclear antibodies (ANA): selective use of central nuclear antigens as a rational basis for screening by ELISA. J Autoimmun 13(1):95–102
Aarden LA, de Groot ER, Feltkamp TE (1975) Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci 254:505–515
Spronk PE, Bootsma H, Kallenberg CG (1998) Anti-DNA antibodies as early predictor for disease exacerbations in SLE. Guideline for treatment? Clin Rev Allergy Immunol 16(3):211–218
Swaak AJ, Nossent JC, Smeenk RJ (1991) Prognostic factors in systemic lupus erythematosus. Rheumatol Int 11(3):127–132
Petri M (1995) Clinical features of systemic lupus erythematosus. Curr Opin Rheumatol 7(5):395–401
Petri M, Barr SG, Zonana-Nach A, Magder L (1999) Measures of disease activity, damage, and health status: the Hopkins Lupus Cohort experience. J Rheumatol 26(2):502–503
Bootsma H, Spronk P, Derksen R, de Boer G, Wolters-Dicke H, Hermans J et al (1995) Prevention of relapses in systemic lupus erythematosus. Lancet 345(8965):1595–1599
Arce-Salinas A, Cardiel MH, Guzman J, Alcocer-Varela J (1996) Validity of retrospective disease activity assessment in systemic lupus erythematosus. J Rheumatol 23(5):846–849
FitzGerald JD, Grossman JM (1999) Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients. Lupus 8(8):638–644
Barr SG, Zonana-Nacach A, Magder LS, Petri M (1999) Patterns of disease activity in systemic lupus erythematosus. Arthritis Rheum 42(12):2682–2688
Wluka AE, Liang MH, Partridge AJ, Fossel AH, Wright EA, Lew RA et al (1997) Assessment of systemic lupus erythematosus disease activity by medical record review compared with direct standardized evaluation. Arthritis Rheum 40(1):57–61
Haga HJ, Brun JG, Rekvig OP, Wetterberg L (1999) Seasonal variations in activity of systemic lupus erythematosus in a subarctic region. Lupus 8(4):269–273
Acknowledgement
This study was supported by grants from Helse Nord and Tromsø Reumatiker Forening.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
van den Berg, L., Nossent, H. & Rekvig, O. Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus. Clin Rheumatol 25, 347–352 (2006). https://doi.org/10.1007/s10067-005-0047-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-005-0047-7